Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial

Autor: Paolo A. Ascierto, Milena Casula, Jenny Bulgarelli, Marina Pisano, Claudia Piccinini, Luisa Piccin, Antonio Cossu, Mario Mandalà, Pier Francesco Ferrucci, Massimo Guidoboni, Piotr Rutkowski, Virginia Ferraresi, Ana Arance, Michele Guida, Evaristo Maiello, Helen Gogas, Erika Richtig, Maria Teresa Fierro, Celeste Lebbe, Hildur Helgadottir, Paola Queirolo, Francesco Spagnolo, Marco Tucci, Michele Del Vecchio, Maria Gonzales Cao, Alessandro Marco Minisini, Sabino De Placido, Miguel F. Sanmamed, Domenico Mallardo, Miriam Paone, Maria Grazia Vitale, Ignacio Melero, Antonio M. Grimaldi, Diana Giannarelli, Reinhard Dummer, Vanna Chiarion Sileni, Giuseppe Palmieri

Publikováno v: Nature Communications, Vol 15, Iss 1, Pp 1-12 (2024)

Abstract No prospective data were available prior to 2021 to inform selection between combination BRAF and MEK inhibition versus dual blockade of programmed cell death protein-1 (PD-1) and cytotoxic T lymphocyte antigen-4 (CTLA-4) as first-line treat

Externí odkaz: https://doaj.org/article/2b98c18ea9d84e45baec87cc1752497f

Neoadjuvant plus adjuvant combined or sequenced vemurafenib, cobimetinib and atezolizumab in patients with high-risk, resectable BRAF-mutated and wild-type melanoma: NEO-TIM, a phase II randomized non-comparative study

Autor: Paolo A. Ascierto, Eleonora Cioli, Vanna Chiarion-Sileni, Pietro Quaglino, Francesco Spagnolo, Massimo Guidoboni, Michele Del Vecchio, Ketty Peris, Paola Queirolo, Luisa Fioretto, Corrado Caracò, Miriam Paone, Antonio Sorrentino, Mariaelena Capone, Diana Giannarelli, Gerardo Ferrara, Daniela Massi, Claudia Trojaniello

Publikováno v: Frontiers in Oncology, Vol 13 (2023)

BackgroundFollowing the increased survival of patients with metastatic melanoma thanks to immunotherapy and targeted therapy, neoadjuvant approaches are being investigated to address the unmet needs of unresponsive and intolerant patients. We aim to

Externí odkaz: https://doaj.org/article/881f19fac9d8492d94ad90ae1c453ee7

4-year survival and biomarkers evaluation from a phase II study of sequential immunotherapy and targeted therapy for metastatic BRAF V600-mutated melanoma (SECOMBIT)

Autor: Paolo Antonio Ascierto, Milena Casula, Jenny Bulgarelli, Marina Pisano, Claudia Piccinini, Luisa Piccin, Antonio Cossu, Mario Mandalà, Pier Francesco Ferrucci, Piotr Rutkowski, Virginia Ferraresi, Ana Arance, Michele Guida, Evaristo Maiello, Helen Gogas, Erika Richtig, Maria Teresa Fierro, Celeste Lebbe, Hildur Helgadottir, Paola Queirolo, Francesco Spagnolo, Marco Tucci, Michele Del Vecchio, Maria Gonzales Cao, Alessandro Marco Minisini, Sabino De Placido, Miguel F Sanmamed, Domenico Mallardo, Miriam Paone, Maria Grazia Vitale, Ignacio Melero, Antonio M Grimaldi, Diana Giannarelli, Reinhard Dummer, Vanna Chiarion Sileni, Giuseppe Palmieri

4-year survival data of clinical trial SECOMBIT

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12ba52afcf11d36bbf36d85b09367c1d

Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab

Autor: Paolo A. Ascierto, Mariaelena Capone, Domenico Mallardo, Vito Vanella, Gabriele Madonna, Corrado Caracò, Miriam Paone, Giuseppe Palmieri, Ernesta Cavalcanti, Ester Simeone, Diana Giannarelli, Lucia Festino, Antonio M. Grimaldi

Publikováno v: Journal of immunotherapy (Online) 6 (2018): 74–84. doi:10.1186/s40425-018-0383-1
info:cnr-pdr/source/autori:Capone M, Giannarelli D, Mallardo D, Madonna G, Festino L, Grimaldi AM, Vanella V, Simeone E, Paone M, Palmieri G, Cavalcanti E, Caracò C, Ascierto PA/titolo:Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with ad-vanced melanoma treated with nivolumab/doi:10.1186%2Fs40425-018-0383-1/rivista:Journal of immunotherapy (Online)/anno:2018/pagina_da:74/pagina_a:84/intervallo_pagine:74–84/volume:6
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-7 (2018)
Journal for Immunotherapy of Cancer

Background Previous studies have suggested that elevated neutrophil-to-lymphocyte ratio (NLR) is prognostic for worse outcomes in patients with a variety of solid cancers, including those treated with immune checkpoint inhibitors. Methods This was a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0dfb5a3c0d825844ede83b376d057006
https://doi.org/10.1186/s40425-018-0383-1

Serious haematological toxicity during and after ipilimumab treatment: a case series

Autor: Paolo A. Ascierto, Marcello Curvietto, Ester Simeone, Assunta Esposito, Antonio M. Grimaldi, Marco Palla, Nicola Mozzillo, Miriam Paone

Publikováno v: Journal of Medical Case Reports

Introduction Immunotherapy with the anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody ipilimumab has been shown to improve overall survival in previously treated and treatment-naïve patients with unresectable stage III or IV melanoma. Consis

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cdaf5361e9a6862a592c17f7db6f674d
https://doi.org/10.1186/1752-1947-8-240